3Bae YA, Lee KS, Han J, et al. Marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue: Imaging findings in 21 patients. Chest, 2008, 133(2) :433-440.
4Juweid ME, Cheson BD. Positron-emission tomography and as- sessment of cancer therapy. N Engl J Med, 2006, 354 (5) : 496- 507.
5Hoffmann M, Kletter K, Becherer A, et al. 18F-fluorodeoxyglu- cose positron emission tomography (18 F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology, 2003,64(4) :336-340.
6Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidi- ty in lymphoma readdressed: A study of 766 patients. J Nuel Med, 2010,51(1):25 30.
7Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detec- tion and staging of extranodal marginal zone lymphomas of the MALT type: A report of 42 cases. Ann Oncol, 2005, 16(3) :473- 480.
8Alinari L, Castellucci P, Elstrom R, et al. 18F_FDG PET in mu- cosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lym- phoma, 2006,47(10):2096 2101.
9Hoffmann M, Wohrer S, Becherer A, et al. lSF-Fluoro deoxy- glucose positron emission tomography in lymphoma of mucosa as- sociated lymphoid tissue: Histology makes the difference. Ann Oncol, 2006,17 (12) : 1761-1765.
10Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro- deoxyglucose positron emission tomography scan in the evalua- tion and follow-up of patients with low-grade lymphomas. Canc- er, 2006,107(1) :175-183.
